Development And Clinical Evaluation Of A Depth Of Anaesthesia Monitor
Funder
National Health and Medical Research Council
Funding Amount
$424,785.00
Summary
Waking up during surgery (awareness under anaesthesia) is a frightening reality for some patients. Although uncommon (occurring in about 1 in 1000 operations), it remains one of the main concerns of patients before their surgery. Recent studies (including our own) have demonstrated that processed EEG monitoring using bispectral index (BIS) can markedly reduce the risk of awareness. Other EEG monitors are being developed, but each have weaknesses. As approximately two million Australians have a g ....Waking up during surgery (awareness under anaesthesia) is a frightening reality for some patients. Although uncommon (occurring in about 1 in 1000 operations), it remains one of the main concerns of patients before their surgery. Recent studies (including our own) have demonstrated that processed EEG monitoring using bispectral index (BIS) can markedly reduce the risk of awareness. Other EEG monitors are being developed, but each have weaknesses. As approximately two million Australians have a general anaesthetic each year, about 2000 will suffer an episode of awareness. More than 60 million people around the world have an anaesthetic, and so the problem is substantial. This suggests the potential benefits (health outcomes, commercial gains) are very great. In 2000 less than 5% of US hospitals used BIS monitoring; the current figure in the US is about 69% of the best-rated hospitals (US News and World Report) and 78% of teaching hospitals. A similar rapid growth is occurring in Australia and Europe. We are working with a successful Australian Company (Compumedics Ltd) to develop a better awareness monitor. We plan studies in groups of patients have surgery.Read moreRead less
Lipoceramic Technologies: A Solution To Low And Variable Bioavailability Of Poorly Soluble Anti-inflammatory Drugs
Funder
National Health and Medical Research Council
Funding Amount
$200,600.00
Summary
A novel oral drug delivery platform will be developed that improves the absorption of poorly soluble drugs from the GI tract, leads to improved clinical outcomes and has significant commercial value. This development will be based on the combination of formulation, in vitro analysis and in vivo animal model studies. An advanced prototype formulation will be established for celecoxib (a non-steroidal anti-inflamatory drug) that will be suitable for human phase 1 clinical trials.
We will conduct a clinical trial of the effectiveness of a continuous auditory display of an anesthetized patient's respiratory status. Expired carbon dioxide monitoring has helped reduce respiratory incidents since its widespread introduction in the late 1980s, but a continuous auditory display of respiratory status may reduce incidents further. We will conduct a clinical trial with 10 anaesthetists of continuous auditory respiratory monitoring. Successful outcome may lead to commercial uptake.
Development Of Novel Methods For Non-invasive Measurement Of Cardiac Output And Lung Volume During Anaesthesia
Funder
National Health and Medical Research Council
Funding Amount
$257,970.00
Summary
In Australia approximately 2 million anaesthetic procedures are performed annually. Approximately one patient in 20,000 dies during or shortly after an anaesthetic from complications related to the anaesthetic itself, and as many as one in 170 suffers severe complications. Mortality and severe morbidity are often ultimately associated with lack of oxygen in the tissues. Oxygen is transported from the lungs to the tissues by the blood. The oxygen content of arterial blood is monitored by pulse ox ....In Australia approximately 2 million anaesthetic procedures are performed annually. Approximately one patient in 20,000 dies during or shortly after an anaesthetic from complications related to the anaesthetic itself, and as many as one in 170 suffers severe complications. Mortality and severe morbidity are often ultimately associated with lack of oxygen in the tissues. Oxygen is transported from the lungs to the tissues by the blood. The oxygen content of arterial blood is monitored by pulse oximetry during every anaesthetic, but blood flow is not. Cardiac output is measured in only a very small proportion of anaesthetised patients using intravenous catheters that pass through the heart to the lungs. This procedure is invasive and is associated with significant morbidity and mortality. At present there is no easy way to monitor cardiac output non-invasively during anaesthesia. Our proposed research project, currently underway in conjunction with an industrial partner, is aimed at the development of a reliable, rapidly repeating, non-invasive method for monitoring total cardiac output and lung volume in every patient who has an anaesthetic. The purpose of the new monitor is to ensure that potential problems with oxygen supply to the tissues are detected and corrected promptly. Our new monitoring technique is computer-controlled, can function without intervention by the anaesthetist and has very few side-effects. It can be added to any anaesthetic machine. Such a measurement technique is likely to have an impact on anaesthesia similar to that of pulse oximetry in the 1980's, and, if suitably adapted, is likely to find applications in other fields, such as intensive care, sports medicine, the respiratory function laboratory and in veterinary medicine.Read moreRead less
The proposed project is part of a research programme aimed at developing a new drug to reduce the side effects of cancer radiotherapy. These side effects result from the radiation damage to normal tissues close to the tumour. Since in many instances the normal tissues at risk are accessible to topical application (eg. skin in breast cancer patients, rectal mucosa in prostate cancer patients, oral mucosa in all patients being treated for tumours in the head and neck region) the concept is very si ....The proposed project is part of a research programme aimed at developing a new drug to reduce the side effects of cancer radiotherapy. These side effects result from the radiation damage to normal tissues close to the tumour. Since in many instances the normal tissues at risk are accessible to topical application (eg. skin in breast cancer patients, rectal mucosa in prostate cancer patients, oral mucosa in all patients being treated for tumours in the head and neck region) the concept is very simple. A drug which makes cells less sensitive to X-rays (these drugs are called radioprotectors) is simply applied topically to the normal tissues at risk. For this purpose, we have developed a new radioprotecting drug called methylproamine which is 100-fold more potent than previously-developed radioprotectors. Unfortunately, methylproamine is not suitable for our purpose because at higher concentrations it is toxic to some cells. This hurdle must be overcome in order to make the project attractive to potential commercial sponsors. Our aim is to modify methylproamine by removing the molecular features that cause the cytotoxicity. We have established that this is feasible, by synthesising and evaluating a small family of methylproamine analogues. Some less toxic family members have already been identified. With this knowledge, we now propose to use special computer programmes to design a much larger family of methylproamine analogues, and to synthesise and test each one in order to identify the most promising candidate for our purpose. Once the efficacy window hurdle is passed, the subsequent milestones to commercialisation and clinical implementation can be addressed, with appropriate sponsorship. An Australian company has already expressed strong interest and is evaluating the opportunity.Read moreRead less